Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;23(1):1-11.
doi: 10.1038/s41435-021-00161-5. Epub 2022 Jan 19.

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Brecht Decraene #  1   2   3 , Yihan Yang #  1   4   5 , Frederik De Smet  2 , Abhishek D Garg  6 , Patrizia Agostinis #  4   5 , Steven De Vleeschouwer #  7   8   9
Affiliations
Review

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Brecht Decraene et al. Genes Immun. 2022 Feb.

Erratum in

Abstract

Immunogenic cell death (ICD) has emerged as a key component of therapy-induced anti-tumor immunity. Over the past few years, ICD was found to play a pivotal role in a wide variety of novel and existing treatment modalities. The clinical application of these techniques in cancer treatment is still in its infancy. Glioblastoma (GBM) is the most lethal primary brain tumor with a dismal prognosis despite maximal therapy. The development of new therapies in this aggressive type of tumors remains highly challenging partially due to the cold tumor immune environment. GBM could therefore benefit from ICD-based therapies stimulating the anti-tumor immune response. In what follows, we will describe the mechanisms behind ICD and the ICD-based (pre)clinical advances in anticancer therapies focusing on GBM.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Clinical setting of ICD-based GBM vaccination.
After GBM resection, ICD will be induced using GBM cells from resected tumor tissue. Next, DC vaccine are prepared ex vivo by exposing autologous DCs to GBM cells dying through ICD. The vaccine contains GBM cells, which are avitalized after ICD induction, and DAMPs, which are either exposed, secreted or released. After applying to the patient, with tumor antigen presented by DCs, effective and GBM-specific T-cell response will be triggered and augmented. Remaining GBM cells will then be targeted to suppress GBM growth and regression. As a result, prolonged survival of the patient might occur.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl J Med. 2015;373:23–34. - PMC - PubMed
    1. Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–93. - PubMed
    1. Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015;6:402. - PMC - PubMed
    1. Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013. - PMC - PubMed
    1. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl J Med. 2016;375:1856–67. - PMC - PubMed